Please assess the completion status of the following clinical trial:

Trial Title: Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* treatment as outpatient~* arterial hypertension~* treatment with a renin inhibitor, ACE inhibitor, ARB, or without RAS blockade~* informed consent~Exclusion Criteria:~* foreseeable difficulties to perform follow up

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aliskiren (Type: None): Patients getting Aliskiren at baseline
- ACE-I/ARB (Type: None): Patients getting ACE-I (angiotensin-converting enzyme inhibitors) or ARB (angiotensin-receptor blockers) at baseline, but not Aliskiren
- No RAS-inhibition (Type: None): Patients getting no drugs at baseline that inhibit the renin-angiotensin-aldosterone-system (RAAS)

Based on this trial design, predict the completion outcome and termination type (if applicable).